Bojana Petreska Kapsarov
Research Subjects
Bojana Petreska Kapsarov has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandar Eftimov
Faculty of Medicine, Institute of Pathology, Ss. Cyril and Methodius University, 1000 Skopje, North Macedonia
1 shared publication - Jasmina Djundeva
University Clinic of Radiotherapy and Oncology, 1000 Skopje, North Macedonia
1 shared publication - Julijana Stefanoska
University Clinic of Radiotherapy and Oncology, 1000 Skopje, North Macedonia
1 shared publication - Marija Simonovska
University Clinic of Radiotherapy and Oncology, 1000 Skopje, North Macedonia
1 shared publication - Marina Vukasinovikj Stoleska
University Clinic of Radiotherapy and Oncology, 1000 Skopje, North Macedonia
1 shared publication
Latest Publications
- Open Access
- 28 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (11) , 4191
PD-L1 Expression as a Predictor of Time to Progression in Metastatic Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors: A Retrospective Single-Center Study
Background/Objectives: Programmed death-ligand 1 (PD-L1) expression is commonly used as a predictive biomarker in metastatic non-small cell lung cancer (NSCLC); however, its clinical utility in real-world settings remains uncertain. This study evaluated the association between PD-L1 expression and treatment outcomes in patients receiving immune checkpoint inhibitors (ICIs). Methods: In this retrospective, single-center study, 86 patients with metastatic NSCLC treated with ICIs (pembrolizumab or atezolizumab) between January 2020 and December 2025 were included. PD-L1 expression was assessed using 22C3 or SP263 assays and categorized as p = 0.84). No statistically significant difference in TTP was observed between PD-L1 p = 0.094), although a numerical trend toward shorter TTP was observed in patients with PD-L1 ≥50%. In multivariate Cox regression analysis, PD-L1 ≥50% was not associated with TTP (hazard ratio [HR] 1.53, 95% confidence interval [CI] 0.77–3.05; p = 0.20). No other clinical variables, including smoking status and liver metastases, were significantly associated with outcomes. Conclusions: In this limited, retrospective single-center cohort with a heterogeneous treatment mix (chemo-immunotherapy and immunotherapy monotherapy), PD-L1 expression was not significantly associated with treatment response or time to progression. While these results should be interpreted cautiously given the modest sample size and the small number of progression events, they are consistent with broader real-world evidence indicating that PD-L1 expression alone may not reliably stratify clinical benefit in metastatic NSCLC. Larger prospective studies integrating PD-L1 with complementary biomarkers are needed to confirm these observations.
- 28 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (11) , 4191
Open AccessPD-L1 Expression as a Predictor of Time to Progression in Metastatic Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors: A Retrospective Single-Center Study
Background/Objectives: Programmed death-ligand 1 (PD-L1) expression is commonly used as a predictive biomarker in metastatic non-small cell lung cancer (NSCLC); however, its clinical utility in real-world settings remains uncertain. This study evaluated the association between PD-L1 expression and treatment outcomes in patients receiving immune checkpoint inhibitors (ICIs). Methods: In this retrospective, single-center study, 86 patients with metastatic NSCLC treated with ICIs (pembrolizumab or atezolizumab) between January 2020 and December 2025 were included. PD-L1 expression was assessed using 22C3 or SP263 assays and categorized as p = 0.84). No statistically significant difference in TTP was observed between PD-L1 p = 0.094), although a numerical trend toward shorter TTP was observed in patients with PD-L1 ≥50%. In multivariate Cox regression analysis, PD-L1 ≥50% was not associated with TTP (hazard ratio [HR] 1.53, 95% confidence interval [CI] 0.77–3.05; p = 0.20). No other clinical variables, including smoking status and liver metastases, were significantly associated with outcomes. Conclusions: In this limited, retrospective single-center cohort with a heterogeneous treatment mix (chemo-immunotherapy and immunotherapy monotherapy), PD-L1 expression was not significantly associated with treatment response or time to progression. While these results should be interpreted cautiously given the modest sample size and the small number of progression events, they are consistent with broader real-world evidence indicating that PD-L1 expression alone may not reliably stratify clinical benefit in metastatic NSCLC. Larger prospective studies integrating PD-L1 with complementary biomarkers are needed to confirm these observations.